raloxifene has been researched along with Bone Loss, Osteoclastic in 1 studies
raloxifene : A member of the class of 1-benzothiophenes that is 1-benzothiophene in which the hydrogens at positions 2, 3, and 6 have been replaced by p-hydroxyphenyl, p-[2-(piperidin-1-yl)ethoxy]benzoyl, and hydroxy groups, respectively.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jain, N | 1 |
| Xu, J | 1 |
| Kanojia, RM | 1 |
| Du, F | 1 |
| Jian-Zhong, G | 1 |
| Pacia, E | 1 |
| Lai, MT | 1 |
| Musto, A | 1 |
| Allan, G | 1 |
| Reuman, M | 1 |
| Li, X | 1 |
| Hahn, D | 1 |
| Cousineau, M | 1 |
| Peng, S | 1 |
| Ritchie, D | 1 |
| Russell, R | 1 |
| Lundeen, S | 1 |
| Sui, Z | 1 |
1 other study available for raloxifene and Bone Loss, Osteoclastic
| Article | Year |
|---|---|
Identification and structure-activity relationships of chromene-derived selective estrogen receptor modulators for treatment of postmenopausal symptoms.
Topics: Animals; Benzopyrans; Bone Resorption; Cell Line, Tumor; Cholesterol; Drug Evaluation, Preclinical; | 2009 |